Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amarillo Biosciences, Inc.
Oral interferon therapy is well tolerated in patients with pulmonary fibrosis
April 8th, 2006
Amarillo Biosciences, Inc., (ABI, AMAR) announced that Lorenz O. Lutherer, MD, PhD, and Cynthia Jumper, MD, professors of internal medicine at Texas Tech University Health Sciences Center, presented data in Atlanta at the Southern Regional Meeting of the Society for Clinical Investigations on low-dose orally administered interferon alpha (IFNa) as a treatment for idiopathic pulmonary fibrosis (IPF). The study, which commenced in 2001 and is ongoing, was funded by a grant from the State of Texas Higher Education Coordinating Board, Applied Technology Program. The IFNa lozenges are being supplied by ABI. IPF is a lung disease of unknown origin that...
Source: Law & Health Weekly (2006-04-08)
|
